A Magnetic Resonance Spectroscopy Method in Characterization of Blood Metabolomics for Alzheimer’s Disease

Abstract

Currently, a definitive AD diagnosis can only be achieved at autopsy, through pathology examinations of brain tissue. No non- or less-invasive examination can yet diagnose and characterize AD during the patient’s life, in turn limiting insights into potential strategies for countering AD modes of progression. Here, using HRMAS MRS, we studied human blood plasma samples obtained from AD and non-AD subjects to reveal potential AD-associated metabolomic changes measurable in blood, which may assist with AD diagnosis and, more importantly, contribute to the development of precision treatments.